WealthTrust Axiom’s AbbVie ABBV Stock Holding History

WealthTrust Axiom’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$866K	Sell	3,441 -17	-0.5%	-$3.66K	0.19%	105
2026 Q1	$752K	Buy	3,458 +557	+19%	+$124K	0.19%	105
2025 Q4	$663K	Hold	2,901	–	–	0.17%	117
2025 Q3	$672K	Buy	2,901 +330	+13%	+$67.2K	0.18%	117
2025 Q2	$477K	Sell	2,571 -80	-3%	-$14.9K	0.14%	139
2025 Q1	$555K	Hold	2,651	–	–	0.17%	119
2024 Q4	$471K	Hold	2,651	–	–	0.14%	139
2024 Q3	$524K	Buy	2,651 +115	+5%	+$21.5K	0.16%	136
2024 Q2	$435K	Sell	2,536 -74	-3%	-$12.3K	0.14%	144
2024 Q1	$475K	Buy	2,610 +1	+0%	+$172	0.15%	141
2023 Q4	$404K	Buy	2,609 +1	+0%	+$146	0.14%	147
2023 Q3	$389K	Sell	2,608 -1,200	-32%	-$176K	0.14%	148
2023 Q2	$513K	Buy	3,808 +1	+0%	+$147	0.17%	125
2023 Q1	$607K	Buy	3,807 +1	+0%	+$153	0.21%	105
2022 Q4	$615K	Buy	3,806 +150	+4%	+$23K	0.21%	99
2022 Q3	$490K	Buy	3,656 +1	+0%	+$143	0.19%	108
2022 Q2	$559K	Buy	3,655 +100	+3%	+$15.3K	0.2%	105
2022 Q1	$576K	Buy	3,555 +1	+0%	+$145	0.18%	117
2021 Q4	$481K	Buy	3,554 +330	+10%	+$39K	0.15%	132
2021 Q3	$347K	Sell	3,224 -10	-0.3%	-$1.14K	0.12%	153
2021 Q2	$364K	Buy	3,234 +1	+0%	+$113	0.12%	153
2021 Q1	$349K	Hold	3,233	–	–	0.12%	151
2020 Q4	$346K	Hold	3,233	–	–	0.13%	145
2020 Q3	$283K	Buy	3,233 +270	+9%	+$25.4K	0.12%	141
2020 Q2	$290K	Hold	2,963	–	–	0.13%	135
2020 Q1	$225K	Buy	2,963 +11	+0.4%	+$937	0.11%	145
2019 Q4	$261K	Sell	2,952 -220	-7%	-$18.3K	0.09%	170
2019 Q3	$240K	Hold	3,172	–	–	0.08%	175
2019 Q2	$230K	Hold	3,172	–	–	0.08%	185
2019 Q1	$255K	Sell	3,172 -43	-1%	-$3.52K	0.09%	171
2018 Q4	$296K	Buy	3,215 +1	+0%	+$88	0.12%	141
2018 Q3	$304K	Sell	3,214 -700	-18%	-$66.4K	0.1%	160
2018 Q2	$362K	Hold	3,914	–	–	0.13%	134
2018 Q1	$370K	Sell	3,914 -165	-4%	-$18.1K	0.13%	138
2017 Q4	$394K	Sell	4,079 -228	-5%	-$21.5K	0.15%	125
2017 Q3	$382K	Hold	4,307	–	–	0.15%	132
2017 Q2	$312K	Buy	4,307 +15	+0.3%	+$1.01K	0.12%	152
2017 Q1	$279K	Hold	4,292	–	–	0.1%	169
2016 Q4	$268K	Buy	4,292 +101	+2%	+$6.17K	0.1%	167
2016 Q3	$264K	Sell	4,191 -225	-5%	-$14.6K	0.1%	162
2016 Q2	$273K	Buy	4,416 +2	+0%	+$122	0.11%	157
2016 Q1	$252K	Buy	4,414 +3	+0.1%	+$167	0.1%	157
2015 Q4	$261K	Buy	4,411 +2	+0%	+$115	0.1%	158
2015 Q3	$239K	Sell	4,409 -43	-1%	-$2.8K	0.1%	159
2015 Q2	$299K	Buy	+4,452	New	+$291K	0.11%	146
2015 Q1	–	Sell	-3,220	Closed	-$210K	–	233
2014 Q4	$210K	Buy	+3,220	New	+$203K	0.07%	194

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WealthTrust Axiom's ABBV Position: Q2 2026 in Review

WealthTrust Axiom reduced its AbbVie (ABBV) stake by 0.49% in Q2 2026, selling an estimated $3.66K and leaving 3,441 shares worth $866K. The position accounts for 0.19% of the portfolio, ranked #105.

WealthTrust Axiom first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

WealthTrust Axiom held 3,441 shares of AbbVie worth $866K as of Q2 2026.
WealthTrust Axiom sold 17 AbbVie shares in Q2 2026, an estimated $3.66K.
AbbVie made up 0.19% of WealthTrust Axiom's portfolio in Q2 2026, its #105 holding.
WealthTrust Axiom first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on WealthTrust Axiom's 13F filing for Q2 2026, filed 11 Aug 2026.